Toremifene Other names: Toremifene citrate

Chemical formula: C₂₆H₂₈ClNO  Molecular mass: 405.96 g/mol  PubChem compound: 3005573

Therapeutic indications

Toremifene is indicated for:

Hormone-dependent metastatic breast cancer in menopause

Population group: women, only adults (18 years old or older)

First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Toremifene is contraindicated in the following cases:

Endometrial hyperplasia

Endometrial hyperplasia

Severe hepatic failure

Hepatic failure stage IV

Congenital QT prolongation, acquired QT prolongation

at least one of
Prolonged QT interval
Long QT syndrome

Hypokalaemia

Hypokalemia

Bradycardia

Bradycardia

Reduced left-ventricular ejection fraction

at least one of
Left ventricular ejection fraction decreased
Left heart failure

Arrhythmias

Arrhythmia

Drugs that prolong the QT interval

Drugs prolonging QT interval

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: FARESTON Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈